Conference

 

 

The Advanced Therapies Congress focuses on tackling challenges at each stage of development to accelerate development of next generation therapies to benefit patients. We bring together decision makers from key biotech and pharma companies, putting forward a good ratio of buyers and sellers in our audience.

With 12 tracks of content, the agenda covers everything from manufacturing, supply chain and logistics, pricing and market access, to developments in key therapeutic areas; cell therapy, gene therapy, gene modified cell therapy, gene editing, stem cells, regenerative medicine, and much more.

2025 Keynotes

 

Tuesday 18th November

Keynote Panel Discussion: State of the Industry Address for Cell and Gene Therapies

Leveraging cutting edge technologies to deliver next generation therapies for patients

AAV Gene Therapy Research and CMC Considerations for Building and Executing a Competitive Pipeline

Wednesday 19th November

Keynote Panel Discussion: Overview of the current regulatory landscape for cell and gene therapies

Transforming treatment of autoimmune disease with effector T-cell therapy

Topics

Evidence, Pricing & Access
  • Ensuring clinical success
  • Tackling large scale regulatory challenges
  • Finding the right framework for reimbursement and market access
  • Cross-border healthcare
  • Outcome based agreements
  • Tackling large scale regulatory challenges
  • Patient informed policy decisions
Gene Modified Cell Therapy
  • Autologous vs allogeneic
  • Tackling solid tumours
  • Combination therapy
  • CAR-T, NK, Gamma-Delta cells
  • Patient stratification and precision medicine approaches
Cell Therapy
  • Stem cells
  • Regenerative Medicine
  • MSCs vs iPSCs
  • Cord blood advancements
Gene Therapy
  • Next generation of gene therapy
  • Moving from rare to more common diseases
  • Tackling immunogenicity
  • Rare diseases & orphan drugs
  • Novel gene delivery systems
  • Gene editing
Cell Therapy Manufacturing
  • Automation & closed systems
  • Scaling up to commercial level
  • Keeping costs low
  • In house vs outsourcing
Viral Vector Manufacturing
  • Continuous manufacturing
  • Scaling up for commercial production
  • In house vs outsourcing
Supply Chain & Logistics
  • Logistics, transportation, distribution & cold chain
  • Moving from clinical to commercial
  • Patient experience
  • Supply chain
  • Point of care delivery
Innovation Showcase
  • Latest in academic research
  • Latest cutting-edge technologies success

 

Advisory Board

 

We have a core group of leading ATMP experts who help us put together the agenda each year. With their expertise we build a programme with the most informative and up to date content each year.

Miguel Forte
President Elect
ISCT
Miguel Forte speaking at Advanced Therapies Congress
David Morrow
Scientific Program Manager
EATRIS
David Morrow speaking at Advanced Therapies Congress
Snehal Naik
Head of Regulatory Policy
Spark Therapeutics
Snehal Naik speaking at Advanced Therapies Congress
Joanne Kurtzberg
Professor of Paediatrics and Pathology
Duke University School of Medicine
Joanne Kurtzberg speaking at Advanced Therapies Congress
Sven Kili
CEO
Antion Biosciences
Sven Kili speaking at Advanced Therapies Congress
Nneka Onwudiwe
Former PRO/PE Regulatory Review Officer
Nneka Owudiwe speaking at Advanced Therapies Congress
Tara Britt
Founder and President
Rare Disease Innovations Institute
Tara Britt speaking at Advanced Therapies Congress
Sean Armour
Head of Discovery
Spark Therapeutics
Sean Armour speaking at Advanced Therapies Congress
Albert Ribickas
Assistant Director of Cell Therapy Facility (CTF) Operations
Moffitt Cancer Center
Albert Ribickas speaking at Advanced Therapies Congress
Susan Nichols
Chairwoman of the board
Rare Disease Innovations Institute
Susan Nicols speaking at Advanced Therapies Congress
Angela Justice
Chief People Officer & Head of Medical Affairs
TCR2 Therapeutics
Angela Justice speaking at Advanced Therapies Congress
Jaap Boelens
Chief, Transplatation and Cellular Therapies
MSK Kids, Memorial Sloan Kettering Cancer Center
Jaap Boelens speaking at Advanced Therapies Congress

 

 

SEE AGENDA

 

“High quality speakers, both in scientific/industrial content and the level of speaker sent in to speak - often CSO/CEO. I also appreciated the quality of the companies with stalls and the variation of startup companies to speak with”

Head of Development, Micregen

“It was a great event for anyone in ATMPs. ”

Managing Director, INDICRO Ltd

“Well organized, good turnout, talks of interest for people in the field, a good mix of service and solutions providers."

Chief Scientific Officer, Biointaxis S.L.

“Plenty of engaging talks, well laid out and easy to navigate both between talks and also to make your way through the stalls and displays. The terrapin app also works really well and I had many great conversations with stall holders.”

Cell Therapy Production Supervisor, Anthony Nolan

“Really interactive sessions, lot of commercial booths to discuss with product specialists, well structured talks organisation with focused sessions."

Senior Scientist, Orchard Therapeutics

“It was a great event. Was able to make good connections entrepreneurs, CROs, CDMOs and amazing scientist. Excellent mixture of startups, commercial and science.”

Executive Director, Aila Biotech

"Meeting remains a very nice forum to engage and exchange with our peers in CGT;. Great people and content and lots of opportunities to dialog with experts on our sector."

President and Chief Executive Officer, Co-Founder, NKILT Therapeutics Inc.

 

 

Get Involved with the Advanced Therapies Congress

 

To sponsor or exhibit


Natasha Bangle
natasha.bangle@terrapinn.com
+44 20 3545 5515


Joshua Lloyd
Josh.Lloyd@terrapinn.com
+44 20 4614 9423

 

To speak


Chris Shanks
chris.shanks@terrapinn.com
+44 20 8152 7604